Spots Global Cancer Trial Database for Caelyx Adjuvant in Elderly Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Caelyx Adjuvant in Elderly Breast Cancer
Official Title: An Open Label Phase II Trial to Investigate the Cardiac Effects of Pegylated Liposomal Doxorubicine (Caelyx) in Elderly Breast Cancer Patients With New Imaging and Biochemical Techniques.
Study ID: NCT00284336
Study Description
Brief Summary: This is an open label Phase II study in elderly patients (65y or older) with early breast cancer who are candidate for adjuvant chemotherapy. A scheme with liposomal doxorubicin (Caelyx) and cyclophosphamide (endoxan) will be used. The aim is to study the cardiac effects of liposomal doxorubicin with new non-invasive techniques, ie strain rate imaging, classical echocardiography, and special blood tests measuring troponin I and BNP.
Detailed Description:
Eligibility
Minimum Age: 65 Years
Eligible Ages: OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
UZ gent, Gent, , Belgium
UH gasthuisberg, Leuven, , Belgium
Contact Details
Name: hans wildiers, MD PhD
Affiliation: UH gasthuisberg Leuven
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
